Supplementary Figure 6. Patient Survival is Associated with Low/High ZDHHC17-MAP2K4 Co-expression
(A, B) Cumulative overall survival (A) and disease-free survival (B) of patients with GBM with low/high ZDHHC17-MAP2K4 co-expression levels (based on median ZDHHC17 and MAP2K4 levels, respectively) estimated using the Kaplan-Meier method and compared with the log-rank test in the same set of patients (**p < 0.01). control, ZDHHC17 shRNA, or MAP2K4 shRNA, or treated with genistein (2.5 μM). Data represent the means ± SD from three separate experiments (ns, non significant; *p < 0.05; **p < 0.01; ***p < 0.001, unpaired t test).
Supplementary Figure 7
(C-F) Transwell analysis of (C, E) migratory and (D, F) invasive (C, D) GBM0378 cells or (E, F) GBM1492 cells stably transfected with control, ZDHHC17 shRNA, or MAP2K4 shRNA, or treated with genistein (2.5 μM). Data represent the means ± SD from three separate experiments (ns, not significant; **p < 0.01; ***p < 0.001, unpaired t test). Scale bar, 500 μm.
(G, H) Colonies formed by 200 viable GSCs from (G) GBM0378 cells or (H) GBM1492 cells stably transfected with control, ZDHHC17 shRNA, or MAP2K4 shRNA, or treated with genistein (2.5 μM). Data represent the means ± SD from three separate experiments (ns, not significant; ***p < 0.001, unpaired t test).
(I, J) Tumor weight of (I) GBM0378 and (J) GBM1492 PDX mice treated with control, ZDHHC17 shRNA, MAP2K4 shRNA -expressing lentivirus or genstein (n = 5; **p < 0.01; ***p < 0.001). Percentage of Ki-67 positive-stained cells in tumor of PDX mice. Scale bar, 200 μm.
Supplementary Figure 11
Supplementary Figure 11 . JNK/p38 Activation is a Key Effector in ZDHHC17-Medited Glioblastoma Multiforme Malignant Progression (A -D) Transwell analysis of migratory (A) and invasive (B) cells, or clonogenic survival of (C) or self-renewal of glioma stem cells, as determined by number of neurospheres formed, from (D) U118MG or SW1088 cells transfected with indicated dsRNA, plasmid, or further treated with JNK agonist, anisomycin (10 μM); p38 agonist, P79350 (5 μM); p-JNK inhibitor, JNK-IN-8 (20 μM); or p-p38 inhibitor, PH-797804 (2.5 μM). Data represent the means ± SD from three separate experiments (ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, unpaired t test).
